Six-, Nine-Month Regimens Containing Bedaquiline Are Effective, Safe For Treating Patients With MDR TB, Study Suggests

Pulmonology Advisor (11/6, Stong) reports, “In tuberculosis (TB), 6- and 9-month regimens containing bedaquiline are effective and safe for treating patients with multidrug-resistant (MDR) disease, according to study findings.” The researchers said, “These data confirm the value of the 9-month regimen recommended in current WHO guidelines and support the use of a 6-month regimen.” The findings were published in The Lancet Respiratory Medicine.